BIIB:NGS-Biogen Inc. (USD)

EQUITY | Drug Manufacturers - General | Nasdaq Global Select

Last Closing

USD 216.34

Change

+4.32 (+2.04)%

Market Cap

USD 69.21B

Volume

1.25M

Analyst Target

USD 305.39
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

+0.14 (+0.19%)

USD 220.75B
AMGN Amgen Inc

+0.60 (+0.22%)

USD 146.44B
SNY Sanofi ADR

-0.23 (-0.47%)

USD 119.97B
GILD Gilead Sciences Inc

+0.15 (+0.23%)

USD 91.17B
GRFS Grifols SA ADR

+0.11 (+1.75%)

USD 4.95B
AMRN Amarin Corporation PLC

+0.01 (+1.72%)

USD 0.35B
SCLX Scilex Holding Company

+0.02 (+2.29%)

USD 0.16B
MIRA MIRA Pharmaceuticals Inc. Comm..

-0.04 (-4.47%)

USD 0.02B
SCLXW Scilex Holding Company

-0.02 (-8.29%)

N/A

ETFs Containing BIIB

UBIO 6.30 % 0.95 %

N/A

N/A
BIS ProShares UltraShort Nasd.. 6.12 % 0.95 %

-0.34 (0.81%)

USD 3.90M
DIP ETF Series Solutions 4.41 % 0.00 %

+0.23 (+0.81%)

USD 1.15M
BBH VanEck Biotech ETF 4.17 % 0.35 %

+0.82 (+0.81%)

USD 0.45B
IBRN iShares Trust - iShares N.. 4.13 % 0.00 %

+0.38 (+0.81%)

USD 3.84M
BTEC:SW iShares Nasdaq US Biotech.. 3.21 % 0.00 %

+0.07 (+0.81%)

USD 0.46B
IBB iShares Biotechnology ETF 3.14 % 0.47 %

+0.82 (+0.81%)

USD 7.79B
IBBQ Invesco Nasdaq Biotechnol.. 3.13 % 0.00 %

+0.18 (+0.81%)

USD 0.03B
MRND 2.44 % 0.00 %

N/A

N/A
BIB ProShares Ultra Nasdaq Bi.. 2.36 % 0.95 %

+0.72 (+0.81%)

USD 0.10B
VCSH Vanguard Short-Term Corpo.. 0.08 % 0.07 %

+0.04 (+0.81%)

USD 35.77B
FLAG 0.00 % 1.52 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

+0.54 (+0.81%)

USD 0.23B
MXDU 0.00 % 0.34 %

N/A

N/A
DQML 0.00 % 0.00 %

N/A

N/A
JAGG 0.00 % 0.07 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.06 (+0.81%)

USD 0.49B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.06 (+0.81%)

USD 0.49B
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

+11.00 (+0.81%)

USD 0.02B
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

+0.10 (+0.81%)

USD 8.18M
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.06 (+0.81%)

USD 0.49B
SCHZ Schwab U.S. Aggregate Bon.. 0.00 % 0.04 %

+0.10 (+0.81%)

USD 7.46B
ZBIO 0.00 % 0.95 %

N/A

N/A
LUMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

+55.00 (+0.81%)

USD 0.01B
USMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

-0.30 (0.81%)

USD 0.01B
XMWD:LSE Xtrackers MSCI World Swap.. 0.00 % 0.00 %

+1.46 (+0.81%)

USD 4.20B
XS2D:LSE Xtrackers S&P 500 2x Leve.. 0.00 % 0.00 %

+6.18 (+0.81%)

USD 0.29B
MVUS:PA Ossiam US Minimum Varianc.. 0.00 % 0.00 %

N/A

USD 0.01B
SPMV:PA Ossiam US Minimum Varianc.. 0.00 % 0.00 %

N/A

USD 7.79M
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

+0.08 (+0.81%)

USD 0.52B
CEM2:F 0.00 % 0.00 %

N/A

N/A
OSX2:F Ossiam Lux - Ossiam US Mi.. 0.00 % 0.00 %

-0.05 (0.81%)

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.08 (+0.81%)

USD 0.52B
CEM2:XETRA 0.00 % 0.00 %

N/A

N/A
OSX2:XETRA Ossiam US Minimum Varianc.. 0.00 % 0.00 %

+0.80 (+0.81%)

USD 0.12B
BIOT 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.40% 30% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.40% 30% F 23% F
Trailing 12 Months  
Capital Gain -21.05% 44% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.05% 44% F 31% F
Trailing 5 Years  
Capital Gain -8.48% 43% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.48% 43% F 39% F
Average Annual (5 Year Horizon)  
Capital Gain 3.51% 56% F 59% D-
Dividend Return 3.51% 56% F 56% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 25.03% 44% F 70% C-
Risk Adjusted Return 14.02% 56% F 53% F
Market Capitalization 69.21B 56% F 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - General) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.00 57% 35%
Price/Book Ratio 2.14 56% 46%
Price / Cash Flow Ratio 20.49 33% 14%
Price/Free Cash Flow Ratio 18.64 11% 13%
Management Effectiveness  
Return on Equity 8.24% 57% 72%
Return on Invested Capital 5.61% 30% 70%
Return on Assets 4.58% 67% 85%
Debt to Equity Ratio 45.87% 80% 42%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector